Clinicopathological and prognostic value of CD24 expression in breast cancer: a meta-analysis.
BACKGROUND
A number of studies have been conducted to explore the relationship between CD24 expression and the prognosis of breast cancer; however, the results remain inconsistent. Therefore, we performed this meta-analysis to clarify the impact of CD24 expression on clinicopathological features and prognosis of breast cancer.


METHODS
A comprehensive literature search for relevant studies was performed, and statistical analysis was conducted using Stata software.


RESULTS
Twenty studies, including 5,179 cases, were included in this meta-analysis. The pooled analysis indicated that CD24 expression was associated with lymph node invasion (odds ratio [OR] = 0.68, for negative vs. positive, 95% confidence interval [95% CI], 0.53-0.87, p = 0.002) and TNM stage (OR = 0.63, for I + II vs. III + IV, 95% CI, 0.49-0.81, p<0.001). The prognosis analysis also suggested CD24 overexpression indicated a poorer 5-year overall survival (OS) rate (relative risk ratio [RR] = 0.93, 95% CI, 0.86-0.99, p = 0.03) and 5-year disease-free survival (DFS) rate (RR = 0.90, 95% CI, 0.83-0.98, p = 0.02). However, CD24 expression had no correlation with tumor size, tumor grade, distance metastasis, estrogen receptor (ER) status, progesterone receptor (PR) status, or HER2 status.


CONCLUSIONS
Our results suggest that higher CD24 expression is significantly associated with lower OS rate, lower DFS rate and some clinicopathological factors such as lymph node invasion and TNM stage. This meta-analysis suggested that CD24 is an efficient prognostic factor in breast cancer.
Department of General Surgery, The Second Xiangya Hospital, Central South University, Changsha - PR China.
Gao
G
Liu
Department of General Surgery, The Second Xiangya Hospital, Central South University, Changsha - PR China.
Guo-Xing
GX
Liu
Department of General Surgery, The Second Xiangya Hospital, Central South University, Changsha - PR China.
Yu
Y
Fang
Department of General Surgery, The Second Xiangya Hospital, Central South University, Changsha - PR China.
Zhen-Yu
ZY
Cao
Department of General Surgery, The Second Xiangya Hospital, Central South University, Changsha - PR China.
Hui-Hui
HH
Du
Department of General Surgery, The Second Xiangya Hospital, Central South University, Changsha - PR China.
Jie
J
Fu
Department of General Surgery, The Second Xiangya Hospital, Central South University, Changsha - PR China.
Ke
K
Qian
D014408:Biomarkers, Tumor / Q000235:genetics*; D001943:Breast Neoplasms / Q000235:genetics* / Q000473:pathology; D051927:CD24 Antigen / Q000235:genetics*; D018572:Disease-Free Survival; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D008207:Lymphatic Metastasis; D009361:Neoplasm Invasiveness / Q000235:genetics; D009362:Neoplasm Metastasis; D009367:Neoplasm Staging; D011379:Prognosis; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000235:genetics; D011980:Receptors, Progesterone / Q000235:genetics
D014408:Biomarkers, Tumor; D051927:CD24 Antigen; D018719:Erb-b2 Receptor Tyrosine Kinases; D011980:Receptors, Progesterone; C508053:ERBB2 protein, human